Reata Pharmaceuticals Inc (RETA) Expected to Announce Earnings of -$0.82 Per Share
Wall Street brokerages predict that Reata Pharmaceuticals Inc (NASDAQ:RETA) will announce ($0.82) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Reata Pharmaceuticals’ earnings, with estimates ranging from ($0.99) to ($0.65). Reata Pharmaceuticals reported earnings of ($0.50) per share in the same quarter last year, which indicates a negative year over year growth rate of 64%. The company is scheduled to report its next quarterly earnings report on Monday, November 12th.
According to Zacks, analysts expect that Reata Pharmaceuticals will report full year earnings of ($2.59) per share for the current year, with EPS estimates ranging from ($2.90) to ($2.26). For the next year, analysts expect that the company will report earnings of ($3.49) per share, with EPS estimates ranging from ($4.16) to ($3.15). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Reata Pharmaceuticals.
Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($1.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.34). The business had revenue of $7.57 million for the quarter, compared to analyst estimates of $9.11 million.
In other Reata Pharmaceuticals news, Director James Edward Bass bought 888 shares of the stock in a transaction that occurred on Wednesday, July 25th. The shares were bought at an average price of $78.34 per share, for a total transaction of $69,565.92. Following the acquisition, the director now directly owns 51,543 shares of the company’s stock, valued at approximately $4,037,878.62. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Elaine Castellanos sold 7,336 shares of the company’s stock in a transaction dated Monday, July 23rd. The stock was sold at an average price of $50.81, for a total transaction of $372,742.16. Following the completion of the sale, the insider now owns 140 shares in the company, valued at approximately $7,113.40. The disclosure for this sale can be found here. 31.69% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp raised its holdings in shares of Reata Pharmaceuticals by 41.5% in the 2nd quarter. Northern Trust Corp now owns 183,930 shares of the company’s stock worth $6,432,000 after acquiring an additional 53,946 shares during the last quarter. Wallace Capital Management Inc. acquired a new stake in shares of Reata Pharmaceuticals in the 2nd quarter worth about $271,000. Bank of New York Mellon Corp raised its holdings in shares of Reata Pharmaceuticals by 33.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 65,587 shares of the company’s stock worth $2,294,000 after acquiring an additional 16,473 shares during the last quarter. Sio Capital Management LLC acquired a new stake in shares of Reata Pharmaceuticals in the 2nd quarter worth about $1,533,000. Finally, MetLife Investment Advisors LLC raised its holdings in shares of Reata Pharmaceuticals by 72.7% in the 2nd quarter. MetLife Investment Advisors LLC now owns 7,732 shares of the company’s stock worth $270,000 after acquiring an additional 3,255 shares during the last quarter. Institutional investors own 46.63% of the company’s stock.
RETA traded up $2.01 during trading on Friday, reaching $61.23. 277,425 shares of the stock traded hands, compared to its average volume of 294,275. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt-to-equity ratio of -0.47. The stock has a market capitalization of $2.43 billion, a P/E ratio of -30.77 and a beta of 2.79. Reata Pharmaceuticals has a 12 month low of $19.31 and a 12 month high of $99.50.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Featured Story: Cash Flow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.